Aplysin induces apoptosis in glioma cells through HSP90/AKT pathway

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Glioma is a prevalent and challenging malignancy with limited effective treatments.
• The PI3K/AKT signaling pathway is crucial for glioma cell survival and proliferation.
• Novel therapeutic strategies targeting this pathway are urgently needed.

Purpose of the Study:

• To investigate the anti-glioma effects of aplysin on GL26 glioma cells.
• To elucidate the underlying molecular mechanisms of aplysin's action.
• To evaluate aplysin's efficacy in an in vivo glioma model.

Main Methods:

• In vitro studies using GL26 glioma cells to assess viability, cell cycle arrest, and apoptosis.
• Western blot analysis to examine the impact of aplysin on the Heat shock protein 90/AKT complex and p-AKT expression.
• In vivo studies involving mice bearing gliomas to evaluate tumor growth and survival rates.

Main Results:

• Aplysin significantly suppressed glioma cell viability in a dose- and time-dependent manner.
• Aplysin induced G0/G1 cell cycle arrest and apoptosis in glioma cells.
• Aplysin treatment impaired the formation of the Heat shock protein 90/AKT complex, reducing p-AKT levels.
• In vivo, aplysin reduced tumor weight and prolonged the survival time of glioma-bearing mice.

Conclusions:

• Aplysin exhibits potent anti-proliferative and pro-apoptotic effects on glioma cells in vitro, potentially via PI3K/AKT pathway inhibition.
• Aplysin demonstrates significant anti-tumor activity in vivo, improving survival in a mouse glioma model.
• Aplysin represents a promising novel therapeutic candidate for glioma treatment.